David T. Curiel

This study encapsulates AAVs into protein vault nanoparticles to bypass neutralizing antibodies, enabling effective gene therapy despite preexisting immunity.

This paper develops a method for targeted gene delivery using adenovirus conjugated with antibody molecular glues, showing enhanced gene transfer to specific cell types in vitro and in vivo.

This study shows that mucosal adenoviral-vectored vaccines provide durable protection against XBB.1.16 infection in nonhuman primates, outperforming intramuscular boosting in reducing virus replication in both upper and lower airways.

This paper introduces a novel gene therapy platform using covalently linked adenovirus-AAV complexes to improve co-infection efficiency and reduce AAV dose requirements.